Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
6025.5000 65.00 (1.09%)
NSE May 09, 2025 15:31 PM
Volume: 450.0K
 

6025.50
1.09%
ICICI Securities Limited
Revenues grew 44.3% YoY to | 1285 crore against I-direct estimate of | 1012.4 crore led by 1) capacity addition, 2) advantage of supply constraints from China and 3) currency tailwinds EBITDA margins rose 887 bps to 40.0% (I-direct estimate: 36.0%) mainly due to currency tailwinds, operational leverage. EBITDA grew 85.5% YoY to | 514.1 crore (I-direct estimate: | 364.5 crore) Net profit grew 92.3% to | 397.7 crore (I-direct estimate: | 275.1...
Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.
More from Divi's Laboratories Ltd.
Recommended